Because ALOX15 expression depends on IL-4 and IL-13, it has been suggested that dupilumab may counter type 2 inflammation in chronic rhinosinusitis in part by suppressing an IL-4/IL-13/ALOX15 M2 macrophage signaling axis72,73. Here, IL4 is linked to chronic rhinosinusitis.